Shanghai Fosun Pharmaceutical (600196) Q3 2025 earnings summary

Executive summary

• Revenue for the first three quarters of 2025 was RMB 29,393 million, down 4.91% year-over-year, mainly due to centralized and volume-based procurement, while innovative drug revenue grew 18.09% to over RMB 6,700 million.

• Net profit attributable to shareholders rose 25.50% year-over-year to RMB 2,523 million, driven by gains from asset sales, including United Family Healthcare.

• Excluding one-off gains, net profit was RMB 1,573 million, down 14.32% year-over-year, reflecting revenue decline and increased investment-stage losses.

• R&D investment for the first three quarters totaled RMB 3,998 million, up 2.12% year-over-year, with Q3 R&D expenses up 28.81%, focused on nuclear medicine, cell therapy, and global clinical studies.

• Operating cash flow for the first three quarters reached RMB 3,382 million, up 13.23% year-over-year.

Financial highlights

• Gross margin remained stable at 48.2% (vs. 48.6% in 3Q24), with selling and distribution expense ratio unchanged at 21.3%.

• Q3 revenue was RMB 9.88 billion, down 5.46% year-over-year.

• Q3 net profit attributable to shareholders was RMB 821 million, up 4.52% year-over-year.

• Cash and bank balances stood at RMB 11,478 million, down from RMB 13,524 million in 3Q24.

• Debt-to-asset ratio was stable at 48.5%.

Outlook and guidance

• Continued focus on innovative drugs and high-value devices to drive future growth and optimize asset and financial structure.

• Ongoing optimization of asset structure and acceleration of cash return.

• Emphasis on R&D resource allocation and pipeline advancement, especially in high-potential areas.

• Strengthening control over selling expenses and maintaining investment in market development for new products.